Biologic behavior of and @entity876 overexpression in multifocal XXXX of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.

@entity1364 @entity5 @entity876 @entity1358 @entity1758
BACKGROUND: In the treatment of @entity1358 ( @entity1358 ), there is controversy between radical and nephron-sparing surgical treatment because of the risk of @entity5 multifocality. The biologic behavior of multifocal @entity1358 compared with that of unifocal @entity1358 is not well investigated, and the relevance of @entity876 and the proliferation markers @entity1758 and @entity1364 ( @entity1364 ) to multifocal @entity1358 is not yet established. METHODS: In this study, @entity876 protein overexpression was investigated immunohistochemically in 27 multifocal and 65 unifocal clear cell RCCs using a monoclonal antibody (DO-1). The nuclear expression of @entity876 was compared with the expression of @entity1364 and @entity1758 (Ki-67 antigen) and other prognostic factors, including grade and stage. RESULTS: Thirty-three RCCs (35.9%) had @entity876 positive nuclear staining. @entity1758 positivity was significantly higher in @entity876 positive @entity5 than in @entity876 negative @entity5 . @entity1364 positivity was not different in @entity876 positive @entity5 compared with @entity876 negative @entity5 . Proliferation marker expression was not associated with @entity5 focality. @entity876 overexpression was more often found in @entity5 than in multifocal @entity5 . Intracellular accumulation of the @entity876 protein was related to @entity5 grade but not to the T classification of @entity5 stage. In addition, lymph node involvement was significantly associated with @entity876 overexpression in @entity5 of the kidney. Focality did not influence progression free survival. CONCLUSIONS: This study demonstrated that there is no difference in the proliferative activity or biologic behavior of multifocal and @entity5 .
